Therapeutic efficacy and safety of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye

Chinese Journal of Ophthalmology

Volumn 44, Issue 3, 2008, Pages 281-284

  Sun, Xiao Dong ^a   Xu, Wei Qi ^a   Rosenfeld, Philip J ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Angiogenesis inhibitors; Antibodies, monoclonal; Eye diseases; Neovascularization, pathologic

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

HUMAN; OFF LABEL DRUG USE; REVIEW; SUBRETINAL NEOVASCULARIZATION; CHOROIDAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; HUMANS; OFF-LABEL USE; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 57649118684     PISSN: 04124081     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report No. 1. Am J Ophthalmol,2003,136:407-418.
2. Treatment of age-related macular degeneration with photodynamic therapy study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol,2001,119:198-207.
3. Verteporfin in photodynamic therapy study group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial - VIP report No. 1. Ophthalmology,2001,108:841-852.
4. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report No. 3. Ophthalmology,2003,110:667-673.
5. Fedorovich I, Mehr DS, Oz O, et al. Choroidal neovascularization after laser in situ keratomileusis in a patient with presumed ocular histoplasmosis syndrome. Eur J Ophthalmol,2004,14:261-263.
6. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology, 2003, 110: 1517-1525.
7. Marticorena J, Gomez-Ulla F, Fernandez M, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol,2006,142:335-337.
8. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci, 1996, 37: 1929-1934.
9. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol,1997,81:154-162.
10. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med,1994,331:1480-1487.
11. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab: an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med,2003,349:427-434.
12. The eyetech study group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina, 2002,22:143-152.
13. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med,2004,351:2805-2816.
14. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology, 2006,113:642.
15. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006,355:1419-1431.
16. Freeman WR. Avastin and new treatments for AMD: where are we? Retina,2006,26:853-858.
17. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging,2005,36:331-335.
18. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology,2005,112:1035-1047.
19. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vasc Pharmacol, 2002, 39: 225-237.
20. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol,2006,90:1344-1349.
21. Rich RM, Rosenfeld PJ, Puliafito CA. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina,2006,26:495-511.
22. Avery RL, Pieramici DJ, Rabana MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology,2006,113:363-372.
23. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol,2007,245:651-655.
24. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina,2006,26:383-390.
25. Jonas JB, Harder B, Spandau UH, et al. Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration. Eur J Ophthalmol,2006,16:774-775.
26. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol,2006,142:1-9.
27. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology,2006,113:2002.
28. Bolz M, Michels S, Geitzenauer W, et al. Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol,2007,91:785-789.
29. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci,2006,47:4569-4578.
30. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol,2005,89:1368-1370.
31. Laud K, Spaide RF, Freund KB, et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina,2006,26:960-963.
32. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathologic myopia. Br J Ophthalmol,2007,91:157-160.
33. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol,2007,91:161-165.
34. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology,2006,113:1695.
35. Friedlander SM, Welch RM. Vanishing disc neovascularization following intravitreal bevacizumab (Avastin) injection. Arch Ophthalmol,2006,124:1365.
36. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina, 2006, 26: 699-700.
37. Oshima Y, Sakaguchi H, Gomi F, et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol, 2006,142:155-158.
38. Mason III JO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol,2006,142:685-688.
39. Silva PJ, Jorge R, Alves CR, et al. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularisation in neovascular glaucoma. Acta Ophthalmol Scand, 2006, 84: 556-557.
40. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging,2006,37:148-150.
41. Niemeyer M, Hefner L, Jochmann C, et al. Intravitreal Bevacizumab for recurring choroidal neovascularisation. Ophthalmology,2007,104:158-160.
42. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging,2005,36:336-339.
43. Mason JO 3rd, Albert MA Jr. Vail RIntravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina,2006,26:356-357.
44. Feiner L, Barr EE, Shui YB, et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina,2006,26:882-888.
45. Narayanan R, Mungcal JK, Kenney MC, et al. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci,2006,47:722-728.
46. Narayanan R, Kenney MC, Kamjoo S, et al. Toxicity of indocyanine green (ICG) in combination with light on retinal pigment epithelial cells and neurosensory retinal cells. Curr Eye Res,2005,30:471-478.
47. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina, 2006,26:512-518.
48. Luke M, Warga M, Ziemssen F, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol, 2006,90:1178-1182.
49. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina,2006,26:257-261.
50. Bakri SJ, Cameron JD, McCannel CA, et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol,2006,142:162-164.
51. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina, 2006, 26: 270-274.
52. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab(Avastin). Retina,2006,26:262-269.
53. Ziemssen F, Warga M, Neuhann IM, et al. Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function? Br J Ophthalmol,2006,90:922.
54. Meyer CH, Mennel S, Schmidt JC, et al. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol,2006,90:1207-1208.
55. Singh RP, Sears JE. Retinal pigment epithelial tears after pegaptanib injection for exudative age-related macular degeneration. Am J Ophthalmol,2006,142:160-162.
56. Goldstein M, Heilweil G, Barak A, et al. Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye,2005,19:1315-1324.
57. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology,2005,112:1048-1053.
58. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology, 2006,113:632.